Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT04485559
- Locations
- 🇺🇸
Children's Minnesota, Minneapolis, Minnesota, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04452877
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT04417621
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04310397
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 48
- Registration Number
- NCT04303403
- Locations
- 🇸🇬
National Cancer Centre, Singapore, Singapore
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04294160
- Locations
- 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT04238624
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 75
- Registration Number
- NCT04201457
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- Conditions
- Interventions
- Drug: SotorasibDrug: RMC-4630Drug: AfatinibDrug: MVASI® (bevacizumab-awwb)Drug: AtezolizumabDrug: TNO155Drug: BI 1701963Drug: AMG 404Drug: TrametinibDrug: PembrolizumabDrug: PalbociclibDrug: EverolimusDrug: IV Chemotherapy (Regimen 1)Drug: Carboplatin, pemetrexed, docetaxel, paclitaxelDrug: PanitumumabDrug: IV Chemotherapy (Regimen 2)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1200
- Registration Number
- NCT04185883
- Locations
- 🇺🇸
Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States
🇺🇸Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 455
- Registration Number
- NCT04116541
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.